Login Register Cart 0
Cardiovascular & Hematological Agents in Medicinal Chemistry

Cardiovascular & Hematological Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5257
ISSN (Online): 1875-6182

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Adropin and Spexin Peptides Ameloriate Cardiac Inflammation, Matrix Metalloproteinases, and Vascular Response

Author(s): Gulsun Memiorcid of author, Burak Yazgan*orcid of author and Ebru Tastekinauthors OrcID

Volume 23, Issue 4, 2025

Published on: 09 May, 2025

Page: [286 - 298] Pages: 13

DOI: 10.2174/0118715257346704250324040652

Price: $65

Become a Editorial Board Member
Become a Reviewer
Become a Editor
Become a Section Editor

Abstract

Background: Chronic renal failure (CRF) triggers chronic systemic inflammation and causes vascular calcification, a prominent contributor to the progression of cardiovascular disease. Adropin and spexin peptides regulate energy balance; also, these peptides trigger anti-inflammatory pathways.

Objectives: Our present study aimed to clarify the potentially protective impact of spexin and adropin peptides on cardiovascular inflammation in an adenine-induced chronic renal failure model.

Methods: The CRF model in Sprague-Dawley rats was established by the administration of adenine hemisulfate for ten days. Then, rats were treated with saline or adropin, or/and spexin for four weeks. CRP, CK, and CK-MB levels in serum were measured by autoanalyzer. Aortic contraction- relaxation responses were determined by the organ bath system. H&E, PAS, and Masson's trichrome stainings evaluated histopathological alterations in both aorta and cardiac tissue. Gene expression levels of ILs (IL1β, IL10, IL17A, IL18, IL21, and IL33), MMPs (MMP1, MMP2, MMP3, MMP9, MMP13, and MMP14), NGAL, TGFβ1, TIMP1, and TNFα in cardiac tissue were evaluated by real-time PCR.

Results and Discussion: We found increased CK and CK-MB levels by CRF induction. In addition, IL1β, IL17A, IL18, IL21, MMP1, MMP3, MMP13, and MMP14 increased after CRF progression. While adropin has effects on CK levels, spexin decreases CK-MB levels. Also, adropin and spexin had a nitric oxide-dependent impact on vascular reactivity. Besides, spexin downregulated IL1β, IL10, IL17A, TGFβ1, MMP1, MMP3, MMP9, MMP13, MMP14 and NGAL; however, the adropin peptide had a limited effect.

Conclusion: These results suggest that adropin and spexin have potential preventive roles on vascular damage in CRF progression via modulation of MMPs and inflammatory genes.

Keywords: Adropin, cardiovascular disease, interleukin, matrix metalloproteinase, renal failure, spexin.

« Previous Next »

Graphical Abstract

Graphical abstract illustrating key findings of the study

[1]
Libby, P.; Ridker, P.M.; Hansson, G.K. Progress and challenges in translating the biology of atherosclerosis. Nature, 2011, 473(7347), 317-325.
[http://dx.doi.org/10.1038/nature10146] [PMID: 21593864]
[2]
Bäck, M.; Yurdagul, A., Jr; Tabas, I.; Öörni, K.; Kovanen, P.T. Inflammation and its resolution in atherosclerosis: Mediators and therapeutic opportunities. Nat. Rev. Cardiol., 2019, 16(7), 389-406.
[http://dx.doi.org/10.1038/s41569-019-0169-2] [PMID: 30846875]
[3]
Tuñón, J.; Badimón, L.; Bochaton-Piallat, M.L.; Cariou, B.; Daemen, M.J.; Egido, J.; Evans, P.C.; Hoefer, I.E.; Ketelhuth, D.F.J.; Lutgens, E.; Matter, C.M.; Monaco, C.; Steffens, S.; Stroes, E.; Vindis, C.; Weber, C.; Bäck, M. Identifying the anti-inflammatory response to lipid lowering therapy: A position paper from the working group on atherosclerosis and vascular biology of the European society of cardiology. Cardiovasc. Res., 2019, 115(1), 10-19.
[http://dx.doi.org/10.1093/cvr/cvy293] [PMID: 30534957]
[4]
Bäck, M.; Hansson, G.K. Anti-inflammatory therapies for atherosclerosis. Nat. Rev. Cardiol., 2015, 12(4), 199-211.
[http://dx.doi.org/10.1038/nrcardio.2015.5] [PMID: 25666404]
[5]
Furman, D.; Campisi, J.; Verdin, E.; Carrera-Bastos, P.; Targ, S.; Franceschi, C.; Ferrucci, L.; Gilroy, D.W.; Fasano, A.; Miller, G.W.; Miller, A.H.; Mantovani, A.; Weyand, C.M.; Barzilai, N.; Goronzy, J.J.; Rando, T.A.; Effros, R.B.; Lucia, A.; Kleinstreuer, N.; Slavich, G.M. Chronic inflammation in the etiology of disease across the life span. Nat. Med., 2019, 25(12), 1822-1832.
[http://dx.doi.org/10.1038/s41591-019-0675-0] [PMID: 31806905]
[6]
Sanada, F.; Taniyama, Y.; Muratsu, J.; Otsu, R.; Shimizu, H.; Rakugi, H.; Morishita, R. Source of chronic inflammation in aging. Front. Cardiovasc. Med., 2018, 5, 12.
[http://dx.doi.org/10.3389/fcvm.2018.00012] [PMID: 29564335]
[7]
Ferrucci, L.; Fabbri, E. Inflammageing: Chronic inflammation in ageing, cardiovascular disease, and frailty. Nat. Rev. Cardiol., 2018, 15(9), 505-522.
[http://dx.doi.org/10.1038/s41569-018-0064-2] [PMID: 30065258]
[8]
Kosmas, C.E.; Silverio, D.; Sourlas, A.; Montan, P.D.; Guzman, E.; Garcia, M.J. Anti-inflammatory therapy for cardiovascular disease. Ann. Transl. Med., 2019, 7(7), 147.
[http://dx.doi.org/10.21037/atm.2019.02.34] [PMID: 31157268]
[9]
Kao, T.W.; Huang, C.C. Inflammatory burden and immunomodulative therapeutics of cardiovascular diseases. Int. J. Mol. Sci., 2022, 23(2), 804.
[http://dx.doi.org/10.3390/ijms23020804] [PMID: 35054989]
[10]
Ridker, P.M.; Everett, B.M.; Thuren, T.; MacFadyen, J.G.; Chang, W.H.; Ballantyne, C.; Fonseca, F.; Nicolau, J.; Koenig, W.; Anker, S.D.; Kastelein, J.J.P.; Cornel, J.H.; Pais, P.; Pella, D.; Genest, J.; Cifkova, R.; Lorenzatti, A.; Forster, T.; Kobalava, Z.; Vida-Simiti, L.; Flather, M.; Shimokawa, H.; Ogawa, H.; Dellborg, M.; Rossi, P.R.F.; Troquay, R.P.T.; Libby, P.; Glynn, R.J. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med., 2017, 377(12), 1119-1131.
[http://dx.doi.org/10.1056/NEJMoa1707914] [PMID: 28845751]
[11]
Thomas, B.; Matsushita, K.; Abate, K.H.; Al-Aly, Z.; Ärnlöv, J.; Asayama, K.; Atkins, R.; Badawi, A.; Ballew, S.H.; Banerjee, A.; Barregård, L.; Barrett-Connor, E.; Basu, S.; Bello, A.K.; Bensenor, I.; Bergstrom, J.; Bikbov, B.; Blosser, C.; Brenner, H.; Carrero, J.J.; Chadban, S.; Cirillo, M.; Cortinovis, M.; Courville, K.; Dandona, L.; Dandona, R.; Estep, K.; Fernandes, J.; Fischer, F.; Fox, C.; Gansevoort, R.T.; Gona, P.N.; Gutierrez, O.M.; Hamidi, S.; Hanson, S.W.; Himmelfarb, J.; Jassal, S.K.; Jee, S.H.; Jha, V.; Jimenez-Corona, A.; Jonas, J.B.; Kengne, A.P.; Khader, Y.; Khang, Y.H.; Kim, Y.J.; Klein, B.; Klein, R.; Kokubo, Y.; Kolte, D.; Lee, K.; Levey, A.S.; Li, Y.; Lotufo, P.; El Razek, H.M.A.; Mendoza, W.; Metoki, H.; Mok, Y.; Muraki, I.; Muntner, P.M.; Noda, H.; Ohkubo, T.; Ortiz, A.; Perico, N.; Polkinghorne, K.; Al-Radaddi, R.; Remuzzi, G.; Roth, G.; Rothenbacher, D.; Satoh, M.; Saum, K.U.; Sawhney, M.; Schöttker, B.; Shankar, A.; Shlipak, M.; Silva, D.A.S.; Toyoshima, H.; Ukwaja, K.; Umesawa, M.; Vollset, S.E.; Warnock, D.G.; Werdecker, A.; Yamagishi, K.; Yano, Y.; Yonemoto, N.; Zaki, M.E.S.; Naghavi, M.; Forouzanfar, M.H.; Murray, C.J.L.; Coresh, J.; Vos, T. Global cardiovascular and renal outcomes of reduced GFR. J. Am. Soc. Nephrol., 2017, 28(7), 2167-2179.
[http://dx.doi.org/10.1681/ASN.2016050562] [PMID: 28408440]
[12]
Stevens, L.A.; Li, S.; Wang, C.; Huang, C.; Becker, B.N.; Bomback, A.S.; Brown, W.W.; Burrows, N.R.; Jurkovitz, C.T.; McFarlane, S.I.; Norris, K.C.; Shlipak, M.; Whaley-Connell, A.T.; Chen, S.C.; Bakris, G.L.; McCullough, P.A. Prevalence of CKD and comorbid illness in elderly patients in the United States: Results from the kidney early evaluation program (KEEP). Am. J. Kidney Dis., 2010, 55(3)(Suppl. 2), S23-S33.
[http://dx.doi.org/10.1053/j.ajkd.2009.09.035] [PMID: 20172445]
[13]
Viaene, L.; Behets, G.J.; Heye, S.; Claes, K.; Monbaliu, D.; Pirenne, J.; D’Haese, P.C.; Evenepoel, P. Inflammation and the bone-vascular axis in end-stage renal disease. Osteoporos. Int., 2016, 27(2), 489-497.
[http://dx.doi.org/10.1007/s00198-015-3233-8] [PMID: 26294291]
[14]
Lu, L.C.; Yang, C.W.; Hsieh, W.Y.; Chuang, W.H.; Lin, Y.C.; Lin, C.S. Decreases in plasma MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios in uremic patients during hemodialysis. Clin. Exp. Nephrol., 2016, 20(6), 934-942.
[http://dx.doi.org/10.1007/s10157-015-1221-0] [PMID: 26711243]
[15]
Cheng, Z.; Limbu, M.; Wang, Z.; Liu, J.; Liu, L.; Zhang, X.; Chen, P.; Liu, B. MMP-2 and 9 in chronic kidney disease. Int. J. Mol. Sci., 2017, 18(4), 776.
[http://dx.doi.org/10.3390/ijms18040776] [PMID: 28397744]
[16]
Kapoor, C.; Vaidya, S.; Wadhwan, V.; Hitesh; Kaur, G.; Pathak, A. Seesaw of matrix metalloproteinases (MMPs). J. Cancer Res. Ther., 2016, 12(1), 28-35.
[http://dx.doi.org/10.4103/0973-1482.157337] [PMID: 27072206]
[17]
Wells, J.M.; Gaggar, A.; Blalock, J.E. MMP generated matrikines. Matrix Biol., 2015, 44-46, 122-129.
[http://dx.doi.org/10.1016/j.matbio.2015.01.016] [PMID: 25636538]
[18]
Turkel, I.; Tahtalioglu, S.; Celik, E.; Yazgan, B.; Kubat, G.B.; Ozerklig, B.; Kosar, S.N. Time-course and muscle-specific gene expression of matrix metalloproteinases and inflammatory cytokines in response to acute treadmill exercise in rats. Mol. Biol. Rep., 2024, 51(1), 667.
[http://dx.doi.org/10.1007/s11033-024-09637-9] [PMID: 38780696]
[19]
Azevedo, A.; Prado, A.F.; Antonio, R.C.; Issa, J.P.; Gerlach, R.F. Matrix metalloproteinases are involved in cardiovascular diseases. Basic Clin. Pharmacol. Toxicol., 2014, 115(4), 301-314.
[http://dx.doi.org/10.1111/bcpt.12282] [PMID: 24974977]
[20]
Lyngbakken, M.N.; Myhre, P.L.; Røsjø, H.; Omland, T. Novel biomarkers of cardiovascular disease: Applications in clinical practice. Crit. Rev. Clin. Lab. Sci., 2019, 56(1), 33-60.
[http://dx.doi.org/10.1080/10408363.2018.1525335] [PMID: 30457415]
[21]
Ma, A.; Bai, J.; He, M.; Wong, A.O.L. Spexin as a neuroendocrine signal with emerging functions. Gen. Comp. Endocrinol., 2018, 265, 90-96.
[http://dx.doi.org/10.1016/j.ygcen.2018.01.015] [PMID: 29355530]
[22]
Walewski, J.L.; Ge, F.; Lobdell, H., IV; Levin, N.; Schwartz, G.J.; Vasselli, J.R.; Pomp, A.; Dakin, G.; Berk, P.D. Spexin is a novel human peptide that reduces adipocyte uptake of long chain fatty acids and causes weight loss in rodents with diet-induced obesity. Obesity, 2014, 22(7), 1643-1652.
[http://dx.doi.org/10.1002/oby.20725] [PMID: 24550067]
[23]
Sassek, M.; Kolodziejski, P.A.; Strowski, M.Z.; Nogowski, L.; Nowak, K.W.; Mackowiak, P. Spexin modulates functions of rat endocrine pancreatic cells. Pancreas, 2018, 47(7), 904-909.
[http://dx.doi.org/10.1097/MPA.0000000000001083] [PMID: 29912854]
[24]
Gu, L.; Ma, Y.; Gu, M.; Zhang, Y.; Yan, S.; Li, N.; Wang, Y.; Ding, X.; Yin, J.; Fan, N.; Peng, Y. Spexin peptide is expressed in human endocrine and epithelial tissues and reduced after glucose load in type 2 diabetes. Peptides, 2015, 71, 232-239.
[http://dx.doi.org/10.1016/j.peptides.2015.07.018] [PMID: 26211893]
[25]
Türkel, İ.; Memi, G.; Yazgan, B. Impact of spexin on metabolic diseases and inflammation: An updated minireview. Exp. Biol. Med., 2022, 247(7), 567-573.
[http://dx.doi.org/10.1177/15353702211072443] [PMID: 35068225]
[26]
Yazgan, B.; Türkel, İ.; Özerkliğ, B.; Atakan, M.M.; Aktitiz, S.; Koşar, Ş.N. Exercise and metabolic health: The emerging roles of novel exerkines. Curr. Protein Pept. Sci., 2022, 23(7), 437-455.
[http://dx.doi.org/10.2174/1389203723666220629163524] [PMID: 35770405]
[27]
Turkel, I.; Ozerklig, B.; Yazgan, B.; Ozenc, A.E.; Kubat, G.B.; Simsek, G.; Atakan, M.M.; Kosar, S.N. Systemic and tissue-specific spexin response to acute treadmill exercise in rats. Peptides, 2024, 180, 171281.
[http://dx.doi.org/10.1016/j.peptides.2024.171281] [PMID: 39111593]
[28]
Kolodziejski, P.A.; Pruszynska-Oszmalek, E.; Micker, M.; Skrzypski, M.; Wojciechowicz, T.; Szwarckopf, P.; Skieresz-Szewczyk, K.; Nowak, K.W.; Strowski, M.Z. Spexin: A novel regulator of adipogenesis and fat tissue metabolism. Biochim. Biophys. Acta Mol. Cell Biol. Lipids, 2018, 1863(10), 1228-1236.
[http://dx.doi.org/10.1016/j.bbalip.2018.08.001] [PMID: 30305242]
[29]
Gambaro, S.E.; Zubiría, M.G.; Giordano, A.P.; Portales, A.E.; Alzamendi, A.; Rumbo, M.; Giovambattista, A. “Spexin improves adipose tissue inflammation and macrophage recruitment in obese mice”. Biochim. Biophys. Acta Mol. Cell Biol. Lipids, 2020, 1865(7), 158700.
[http://dx.doi.org/10.1016/j.bbalip.2020.158700] [PMID: 32201217]
[30]
Kumar, K.G.; Trevaskis, J.L.; Lam, D.D.; Sutton, G.M.; Koza, R.A.; Chouljenko, V.N.; Kousoulas, K.G.; Rogers, P.M.; Kesterson, R.A.; Thearle, M.; Ferrante, A.W., Jr; Mynatt, R.L.; Burris, T.P.; Dong, J.Z.; Halem, H.A.; Culler, M.D.; Heisler, L.K.; Stephens, J.M.; Butler, A.A. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab., 2008, 8(6), 468-481.
[http://dx.doi.org/10.1016/j.cmet.2008.10.011] [PMID: 19041763]
[31]
Lian, W.; Gu, X.; Qin, Y.; Zheng, X. Elevated plasma levels of adropin in heart failure patients. Intern. Med., 2011, 50(15), 1523-1527.
[http://dx.doi.org/10.2169/internalmedicine.50.5163] [PMID: 21804276]
[32]
Butler, A.A.; Tam, C.S.; Stanhope, K.L.; Wolfe, B.M.; Ali, M.R.; O’Keeffe, M.; St-Onge, M.P.; Ravussin, E.; Havel, P.J. Low circulating adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans. J. Clin. Endocrinol. Metab., 2012, 97(10), 3783-3791.
[http://dx.doi.org/10.1210/jc.2012-2194] [PMID: 22872690]
[33]
Maciorkowska, M.; Musiałowska, D.; Małyszko, J. Adropin and irisin in arterial hypertension, diabetes mellitus and chronic kidney disease. Adv. Clin. Exp. Med., 2019, 28(11), 1571-1575.
[http://dx.doi.org/10.17219/acem/104551] [PMID: 31756066]
[34]
Lovren, F.; Pan, Y.; Quan, A.; Singh, K.K.; Shukla, P.C.; Gupta, M.; Al-Omran, M.; Teoh, H.; Verma, S. Adropin is a novel regulator of endothelial function. Circulation, 2010, 122(11_suppl_1)(Suppl.), S185-S192.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.109.931782] [PMID: 20837912]
[35]
Sato, K.; Yamashita, T.; Shirai, R.; Shibata, K.; Okano, T.; Yamaguchi, M.; Mori, Y.; Hirano, T.; Watanabe, T. Adropin contributes to anti-atherosclerosis by suppressing monocyte-endothelial cell adhesion and smooth muscle cell proliferation. Int. J. Mol. Sci., 2018, 19(5), 1293.
[http://dx.doi.org/10.3390/ijms19051293] [PMID: 29701665]
[36]
Yazgan, B.; Avcı, F.; Memi, G.; Tastekin, E. Inflammatory response and matrix metalloproteinases in chronic kidney failure: Modulation by adropin and spexin. Exp. Biol. Med. , 2021, 246(17), 1917-1927.
[http://dx.doi.org/10.1177/15353702211012417] [PMID: 34024143]
[37]
Memi, G.; Yazgan, B. Adropin and spexin hormones regulate the systemic inflammation in adenine-induced chronic kidney failure in rat. Chin. J. Physiol., 2021, 64(4), 194-201.
[http://dx.doi.org/10.4103/cjp.cjp_13_21] [PMID: 34472450]
[38]
Ruiz-Ortega, M.; Rayego-Mateos, S.; Lamas, S.; Ortiz, A.; Rodrigues-Diez, R.R. Targeting the progression of chronic kidney disease. Nat. Rev. Nephrol., 2020, 16(5), 269-288.
[http://dx.doi.org/10.1038/s41581-019-0248-y] [PMID: 32060481]
[39]
Düsing, P.; Zietzer, A.; Goody, P.R.; Hosen, M.R.; Kurts, C.; Nickenig, G.; Jansen, F. Vascular pathologies in chronic kidney disease: Pathophysiological mechanisms and novel therapeutic approaches. J. Mol. Med., 2021, 99(3), 335-348.
[http://dx.doi.org/10.1007/s00109-021-02037-7] [PMID: 33481059]
[40]
Yosaee, S.; Soltani, S.; Sekhavati, E.; Jazayeri, S. Adropin- A novel biomarker of heart disease: A systematic review article. Iran. J. Public Health, 2016, 45(12), 1568-1576.
[PMID: 28053922]
[41]
Kashioulis, P.; Lundgren, J.; Shubbar, E.; Nguy, L.; Saeed, A.; Guron, C.W.; Guron, G. Adenine-induced chronic renal failure in rats: A model of chronic renocardiac syndrome with left ventricular diastolic dysfunction but preserved ejection fraction. Kidney Blood Press. Res., 2018, 43(4), 1053-1064.
[http://dx.doi.org/10.1159/000491056] [PMID: 29969785]
[42]
Demircelik, B.; Cakmak, M.; Nazli, Y.; Gurel, O.M.; Akkaya, N.; Cetin, M.; Cetin, Z.; Selcoki, Y.; Kurtul, A.; Eryonucu, B. Adropin: A new marker for predicting late saphenous vein graft disease after coronary artery bypass grafting. Clin. Invest. Med., 2014, 37(5), 338.
[http://dx.doi.org/10.25011/cim.v37i5.22014] [PMID: 25282140]
[43]
Topuz, M.; Celik, A.; Aslantas, T.; Demir, A.K.; Aydin, S.; Aydin, S. Plasma adropin levels predict endothelial dysfunction like flow-mediated dilatation in patients with type 2 diabetes mellitus. J. Investig. Med., 2013, 61(8), 1161-1164.
[http://dx.doi.org/10.2310/JIM.0000000000000003] [PMID: 24113736]
[44]
Paulus, W.J.; Tschöpe, C. A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J. Am. Coll. Cardiol., 2013, 62(4), 263-271.
[http://dx.doi.org/10.1016/j.jacc.2013.02.092] [PMID: 23684677]
[45]
Armstrong, A.W.; Voyles, S.V.; Armstrong, E.J.; Fuller, E.N.; Rutledge, J.C. A tale of two plaques: Convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis. Exp. Dermatol., 2011, 20(7), 544-549.
[http://dx.doi.org/10.1111/j.1600-0625.2011.01308.x] [PMID: 21692858]
[46]
Ramji, D.P.; Davies, T.S. Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets. Cytokine Growth Factor Rev., 2015, 26(6), 673-685.
[http://dx.doi.org/10.1016/j.cytogfr.2015.04.003] [PMID: 26005197]
[47]
Shirazi, L.F.; Bissett, J.; Romeo, F.; Mehta, J.L. Role of inflammation in heart failure. Curr. Atheroscler. Rep., 2017, 19(6), 27.
[http://dx.doi.org/10.1007/s11883-017-0660-3] [PMID: 28432635]
[48]
Carbone, S.; Lee, P.J.H.; Mauro, A.G.; Mezzaroma, E.; Buzzetti, R.; Van Tassell, B.; Abbate, A.; Toldo, S. Interleukin-18 mediates cardiac dysfunction induced by western diet independent of obesity and hyperglycemia in the mouse. Nutr. Diabetes, 2017, 7(4), e258.
[http://dx.doi.org/10.1038/nutd.2017.1] [PMID: 28394363]
[49]
Katkenov, N.; Mukhatayev, Z.; Kozhakhmetov, S.; Sailybayeva, A.; Bekbossynova, M.; Kushugulova, A. Systematic review on the role of il-6 and il-1β in cardiovascular diseases. J. Cardiovasc. Dev. Dis., 2024, 11(7), 206.
[http://dx.doi.org/10.3390/jcdd11070206] [PMID: 39057626]
[50]
Lugrin, J.; Parapanov, R.; Milano, G.; Cavin, S.; Debonneville, A.; Krueger, T.; Liaudet, L. The systemic deletion of interleukin-1α reduces myocardial inflammation and attenuates ventricular remodeling in murine myocardial infarction. Sci. Rep., 2023, 13(1), 4006.
[http://dx.doi.org/10.1038/s41598-023-30662-4] [PMID: 36899010]
[51]
Lin, J.; Kakkar, V.; Lu, X. Impact of matrix metalloproteinases on atherosclerosis. Curr. Drug Targets, 2014, 15(4), 442-453.
[http://dx.doi.org/10.2174/1389450115666140211115805] [PMID: 24517161]
[52]
Wang, M.; Kim, S.H.; Monticone, R.E.; Lakatta, E.G. Matrix metalloproteinases promote arterial remodeling in aging, hypertension, and atherosclerosis. Hypertension, 2015, 65(4), 698-703.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.114.03618] [PMID: 25667214]
[53]
Heo, S.H.; Cho, C.H.; Kim, H.O.; Jo, Y.H.; Yoon, K.S.; Lee, J.H.; Park, J.C.; Park, K.C.; Ahn, T.B.; Chung, K.C.; Yoon, S.S.; Chang, D.I. Plaque rupture is a determinant of vascular events in carotid artery atherosclerotic disease: Involvement of matrix metalloproteinases 2 and 9. J. Clin. Neurol., 2011, 7(2), 69-76.
[http://dx.doi.org/10.3988/jcn.2011.7.2.69] [PMID: 21779294]
[54]
Cavusoglu, E.; Marmur, J.D.; Kassotis, J.T.; Yanamadala, S.; Chopra, V.; Eng, C. Usefulness of plasma matrix Metalloproteinase-3 levels to predict myocardial infarction in men with and without acute coronary syndrome. Am. J. Cardiol., 2016, 117(6), 881-886.
[http://dx.doi.org/10.1016/j.amjcard.2015.12.022] [PMID: 26805660]
[55]
Abbas, A.; Aukrust, P.; Russell, D.; Krohg-Sørensen, K.; Almås, T.; Bundgaard, D.; Bjerkeli, V.; Sagen, E.L.; Michelsen, A.E.; Dahl, T.B.; Holm, S.; Ueland, T.; Skjelland, M.; Halvorsen, B. Matrix metalloproteinase 7 is associated with symptomatic lesions and adverse events in patients with carotid atherosclerosis. PLoS One, 2014, 9(1), e84935.
[http://dx.doi.org/10.1371/journal.pone.0084935] [PMID: 24400123]
[56]
Radosinska, J.; Barancik, M.; Vrbjar, N. Heart failure and role of circulating MMP-2 and MMP-9. Panminerva Med., 2017, 59(3), 241-253.
[http://dx.doi.org/10.23736/S0031-0808.17.03321-3] [PMID: 28399617]
[57]
Zile, M.R.; DeSantis, S.M.; Baicu, C.F.; Stroud, R.E.; Thompson, S.B.; McClure, C.D.; Mehurg, S.M.; Spinale, F.G. Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ. Heart Fail., 2011, 4(3), 246-256.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.110.958199] [PMID: 21350055]
[58]
Zachariah, J.P.; Colan, S.D.; Lang, P.; Triedman, J.K.; Alexander, M.E.; Walsh, E.P.; Berul, C.I.; Cecchin, F. Circulating matrix metalloproteinases in adolescents with hypertrophic cardiomyopathy and ventricular arrhythmia. Circ. Heart Fail., 2012, 5(4), 462-466.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.111.966200] [PMID: 22628530]
[59]
Ravera, A.; Santema, B.T.; de Boer, R.A.; Anker, S.D.; Samani, N.J.; Lang, C.C.; Ng, L.; Cleland, J.G.F.; Dickstein, K.; Lam, C.S.P.; Van Spall, H.G.C.; Filippatos, G.; van Veldhuisen, D.J.; Metra, M.; Voors, A.A.; Sama, I.E. Distinct pathophysiological pathways in women and men with heart failure. Eur. J. Heart Fail., 2022, 24(9), 1532-1544.
[http://dx.doi.org/10.1002/ejhf.2534] [PMID: 35596674]
[60]
Rodrigues, K.E.; Pontes, M.H.B.; Cantão, M.B.S.; Prado, A.F. The role of matrix metalloproteinase-9 in cardiac remodeling and dysfunction and as a possible blood biomarker in heart failure. Pharmacol. Res., 2024, 206, 107285.
[http://dx.doi.org/10.1016/j.phrs.2024.107285] [PMID: 38942342]
[61]
Walewski, J.L.; Ge, F.; Gagner, M.; Inabnet, W.B.; Pomp, A.; Branch, A.D.; Berk, P.D. Adipocyte accumulation of long-chain fatty acids in obesity is multifactorial, resulting from increased fatty acid uptake and decreased activity of genes involved in fat utilization. Obes. Surg., 2010, 20(1), 93-107.
[http://dx.doi.org/10.1007/s11695-009-0002-9] [PMID: 19866242]
[62]
Balagopal, P.B.; de Ferranti, S.D.; Cook, S.; Daniels, S.R.; Gidding, S.S.; Hayman, L.L.; McCrindle, B.W.; Mietus-Snyder, M.L.; Steinberger, J. Nontraditional risk factors and biomarkers for cardiovascular disease: Mechanistic, research, and clinical considerations for youth: a scientific statement from the American heart association. Circulation, 2011, 123(23), 2749-2769.
[http://dx.doi.org/10.1161/CIR.0b013e31821c7c64] [PMID: 21555711]
[63]
Onat, E.; Kocaman, N.; Hancer, S. The protective effects of humanin in rats with experimental myocardial infarction: The role of asprosin and spexin. Heliyon, 2023, 9(8), e18739.
[http://dx.doi.org/10.1016/j.heliyon.2023.e18739] [PMID: 37576267]
[64]
Heijman, J.; Dobrev, D. Spexin hormone signaling and atrial fibrillation: The knowns and unknowns. Circulation, 2024, 150(2), 128-131.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.124.070016] [PMID: 38976612]
[65]
Çiftçi, Y.; Gurger, M.; Gul, E.; Yilmaz, M.; Telo, S.; Atescelik, M.; Cagri, G.; Ali, K. Spexin level in acute myocardial infarction in the emergency department. J. Med. Biochem., 2023, 42(3), 407-411.
[http://dx.doi.org/10.5937/jomb0-39485] [PMID: 37814620]
[66]
Said, M.A.; Nafeh, N.Y.; Abdallah, H.A. Spexin alleviates hypertension, hyperuricaemia, dyslipidemia and insulin resistance in high fructose diet induced metabolic syndrome in rats via enhancing PPAR-ɣ and AMPK and inhibiting IL-6 and TNF-α. Arch. Physiol. Biochem., 2023, 129(5), 1111-1116.
[http://dx.doi.org/10.1080/13813455.2021.1899242] [PMID: 33721543]
[67]
Kuloglu, T.; Aydin, S. Immunohistochemical expressions of adropin and ınducible nitric oxide synthase in renal tissues of rats with streptozotocin-ınduced experimental diabetes. Biotech. Histochem., 2014, 89(2), 104-110.
[http://dx.doi.org/10.3109/10520295.2013.821713] [PMID: 23957703]
[68]
Altamimi, T.R.; Gao, S.; Karwi, Q.G.; Fukushima, A.; Rawat, S.; Wagg, C.S.; Zhang, L.; Lopaschuk, G.D. Adropin regulates cardiac energy metabolism and improves cardiac function and efficiency. Metabolism, 2019, 98, 37-48.
[http://dx.doi.org/10.1016/j.metabol.2019.06.005] [PMID: 31202835]
[69]
Hu, W.; Chen, L. Association of serum adropin concentrations with diabetic nephropathy. Mediators Inflamm., 2016, 2016, 1-5.
[http://dx.doi.org/10.1155/2016/6038261] [PMID: 27546995]
[70]
Ali, I.I.; D’Souza, C.; Tariq, S.; Adeghate, E.A. Adropin is expressed in pancreatic islet cells and reduces glucagon release in diabetes mellitus. Int. J. Mol. Sci., 2024, 25(18), 9824.
[http://dx.doi.org/10.3390/ijms25189824] [PMID: 39337311]
[71]
Zhang, L.; Wu, X.; Li, X.; Chang, X.; Ding, X.; Wang, Q.; Jiang, T.; Wang, G.; Liu, J. Longitudinal changes in serum adropin levels and liver fat content during liraglutide treatment in newly diagnosed patients with type 2 diabetes mellitus and metabolic dysfunction-associated fatty liver disease. Acta Diabetol., 2023, 60(7), 971-979.
[http://dx.doi.org/10.1007/s00592-023-02082-3] [PMID: 37079136]
[72]
Rooban, S.; Senghor, K.A.; Vinodhini, V.; Kumar, J. Adropin: A crucial regulator of cardiovascular health and metabolic balance Metabolites Open, 2024, 23, 100299.
[73]
El Moneem Elfedawy, M.A.; El Sadek Elsebai, S.A.; Tawfik, H.M.; Youness, E.R.; Zaki, M. Adropin a candidate diagnostic biomarker for cardiovascular disease in patients with chronic kidney disease. J. Genet. Eng. Biotechnol., 2024, 22(4), 100438.
[http://dx.doi.org/10.1016/j.jgeb.2024.100438] [PMID: 39674635]
[74]
Berezina, T.A.; Berezin, O.O.; Hoppe, U.C.; Lichtenauer, M.; Berezin, A.E. Adropin predicts asymptomatic heart failure in patients with type 2 diabetes mellitus independent of the levels of natriuretic peptides. Diagnostics, 2024, 14(16), 1728.
[http://dx.doi.org/10.3390/diagnostics14161728] [PMID: 39202216]
[75]
Cho, D.H. Adropin: A new biomarker in coronary artery disease. CMSJ, 2023, 3(1), 85-86.
[http://dx.doi.org/10.51789/cmsj.2023.3.e8]

Rights & Permissions Print Cite
Article Metrics
Pdf icon 31
Html icon 3
Find your institution